Triziston
Triziston: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Trisiston
ATX code: G03AB03
Active ingredient: ethinylestradiol (ethinylestradiol), levonorgestrel (levonorgestrel)
Manufacturer: JENAPHARM GmbH & Co. KG (Germany)
Description and photo update: 2018-26-10
Trizistone is a combined (estrogen-gestagenic) three-phase oral contraceptive.
Release form and composition
Triziston is produced in the form of pills: three types in one package - red-brown, white and mustard color (21 pcs. (6 pcs. Red-brown and white and 9 pcs. Mustard color) in a blister strip, in a cardboard pack 1 or 3 packs).
The active ingredients are ethinyl estradiol and levonorgestrel, their content is in 1 tablet (respectively): red-brown color - 0.03 mg and 0.05 mg, white color - 0.04 mg and 0.075 mg, mustard color - 0.03 mg and 0.125 mg.
Pharmacological properties
Pharmacodynamics
Trizistone is a combined estrogen-progestin oral contraceptive. The estrogenic component is ethinyl estradiol, the gestagenic component is levonorgestrel (a derivative of 19-nortestosterone). The therapeutic effect of the drug is associated with the inhibition of the pituitary secretion of gonadotropic hormones.
In terms of activity, levonorgestrel is superior to the corpus luteum hormone progesterone and its synthetic analogue pregnin. The mechanism of its action is carried out without preliminary metabolic transformations at the receptor level. The influence of levonorgestrel provides a blockade of the release of releasing factors - follicle-stimulating and luteinizing hormones of the hypothalamus. As a result of inhibition of the secretion of gonadotropic hormones by the pituitary gland, the maturation of the egg and its release from the ovary slows down. Ethinylestradiol enhances the contraceptive effect of the drug, maintaining a high viscosity of cervical mucus. This protects the uterine cavity from free entry of sperm.
Regular use of Trizistone, in addition to the contraceptive effect, helps to normalize the menstrual cycle, prevent the development of neoplasms and other gynecological diseases.
Pharmacokinetics
After oral administration, the active substances are absorbed from the gastrointestinal tract quickly and completely. The maximum concentration of ethinyl estradiol in blood plasma is reached after 1.5 hours, levonorgestrel - after 2 hours.
The metabolism of active substances occurs in the liver.
The half-life of the drug is from 2 to 7 hours.
Ethinyl estradiol and levonorgestrel are excreted in breast milk.
60% of levonorgestrel and 40% of ethinyl estradiol are excreted through the kidneys, 40% and 60%, respectively, through the intestines.
Indications for use
According to the instructions, Trizistona is indicated only for women as a contraceptive.
Monophasic dosage forms are used to treat hormone-dependent functional disorders of the menstrual cycle, including premenstrual syndrome, dysmenorrhea, menorrhagia without an organic cause.
Contraindications
- congenital hyperbilirubinemia (Gilbert's syndrome, Dubin-Johnson syndrome, Rotor syndrome);
- liver neoplasms (liver cancer, hemangioma);
- liver failure;
- breast cancer, malignant neoplasms of the endometrium and other organs;
- severe form of cardiovascular and / or cerebrovascular disease, thromboembolism, generalized atherosclerosis, hemorrhagic or ischemic stroke, decompensated chronic heart failure, myocarditis, severe forms of arterial hypertension, heart defects (including history);
- diabetes mellitus disease, accompanied by retinopathy and microangiopathy;
- sickle cell anemia;
- chronic form of hemolytic anemia;
- otosclerosis (including hearing impairment);
- migraine;
- congenital hyperlipidemia;
- a history of idiopathic jaundice or pruritus during a previous pregnancy;
- age over 40;
- vaginal bleeding of unknown origin;
- cystic drift;
- breast-feeding;
- period of pregnancy;
- hypersensitivity to the components of the drug.
With caution, Trizistone should be prescribed for impaired renal function, diseases of the gallbladder and liver, depression, tuberculosis, epilepsy, ulcerative colitis, uterine myoma, mastopathy, in adolescence, when ovulatory cycles are irregular.
Instructions for the use of Triziston: method and dosage
Dragee Triziston is taken orally, swallowed whole and washed down with a sufficient amount of liquid.
With contraception, the woman determines the time of admission for herself independently and strictly observes it throughout the course. It is preferable to take the drug after breakfast or dinner. Since the contraceptive effect is ensured by maintaining a constant concentration of hormones in the blood plasma, the interval between doses should be from 22 to 26 hours and not exceed 36 hours.
Dragee take 1 pc. 1 time per day, starting from the 1st or 5th day of menstrual bleeding [depending on the type of drug used: monophasic (in a package of dragees of the same color), two- or three-phase (in a package of dragees of different colors)], daily. Contraception should be started by taking red-brown pills, then white pills are taken for 6 days and mustard pills for 9 days. After 21 days, when all the pills from the package are taken, there is a break in taking the drug for 7 days, during which menstrual bleeding passes. After a 7-day break, even if the bleeding continues, you should start taking the red-brown dragee from a new package.
If you accidentally skip taking the next dose of the drug at the set time, the pills should be taken as soon as you remember. If the delay does not exceed 12 hours, then the contraceptive effect of Triziston remains. If the missed dose is taken in a period exceeding 36 hours from the moment of taking the previous tablet, the contraceptive effect is impaired. In this regard, until the end of the menstrual cycle, taking pills should be continued and at the same time use barrier methods of contraception.
If, after taking the next dose, a woman has vomiting or diarrhea, there is a risk of incomplete absorption of the drug into the blood and hormonal imbalance. If the symptoms of discomfort disappear within one day, it is recommended to take an additional 1 tablet from the package and continue the cycle. If vomiting and diarrhea continue for several days, then the contraceptive effect of the drug is impaired and barrier contraceptive methods should be used.
When prescribing Triziston for therapeutic purposes, the doctor determines the dose individually. Usually it is 2-3 pcs. in a day. The duration of the course of therapy is 10 days or until the bleeding stops completely.
Side effects
- possible: nausea, vomiting, engorgement of the mammary glands, headache, weight gain, deterioration in mood, coarsening of the voice, spotting during the menstrual cycle, decreased libido;
- in some cases: transient visual disturbances, eyelid edema, discomfort from contact lenses, conjunctivitis (disappear after drug withdrawal);
- rarely: diarrhea, fatigue, increased blood pressure, skin rashes, hypertriglyceridemia, decreased glucose tolerance, hyperglycemia, thrombosis, venous thromboembolism, impaired vaginal secretion, vaginal candidiasis;
- very rare: against the background of prolonged use - generalized itching, chloasma, hearing impairment, cramps of the calf muscles, increased frequency of epileptic seizures, jaundice.
Overdose
Overdose symptoms have not been established.
special instructions
It is recommended to start using Triziston only after consulting a gynecologist, conducting a general medical and gynecological examination, including a study of the mammary glands, liver function, blood pressure control, determination of blood cholesterol concentration, and urinalysis. During the period of using the drug, an examination should be carried out 1 time in 6 months.
Recovery of fertility after drug withdrawal occurs rather quickly (within 1-3 menstrual cycles).
After childbirth or abortion, it is recommended to start using oral contraceptives after the first full menstrual cycle.
The risk of developing vascular pathologies with serious consequences (stroke, myocardial infarction) increases if hormonal contraceptives are used against the background of smoking, especially over the age of 35.
Moderate bleeding during the course of contraception is not a reason for discontinuation of the drug.
Reasons for immediately discontinuing Trizistone include conception, newly developed migraine-like headache, early signs of phlebitis and phlebothrombosis in the form of unusual pain or swelling of veins in the legs, visual impairment, cerebrovascular disorders, stabbing pain when breathing or coughing of unknown etiology, tightness and pain in the chest, increased blood pressure, jaundice.
Women planning a pregnancy should stop taking hormonal contraceptives and use other contraceptives within three months. Only after three menstrual cycles can you become pregnant.
For planned surgical intervention followed by prolonged immobilization, the use of Triziston should be discontinued no later than 1.5 months before the operation.
Application during pregnancy and lactation
The use of Trizistone is contraindicated during gestation and lactation.
If conception occurred during the period of contraception or therapy, the pill should be stopped immediately.
When prescribing the drug during lactation, breastfeeding should be canceled.
Pediatric use
Caution should be given to trizistone during adolescence in girls with irregular ovulatory cycles.
With impaired renal function
Caution should be exercised if kidney function is impaired.
For violations of liver function
The use of Trizistone is contraindicated in liver failure, liver cancer, hemangioma.
Caution is advised if liver function is impaired.
Use in the elderly
You can not appoint Triziston to women over the age of 40.
Drug interactions
With the simultaneous use of Triziston:
- carbamazepine, phenytoin (antiepileptic drugs), barbiturates, pyrazolone derivatives, sulfonamides - can enhance the metabolism of the drug's steroid hormones;
- tetracyclines, ampicillin, rifampicin, neomycin, polymyxin B, chloramphenicol, sulfonamides (antimicrobial agents) - cause a change in the intestinal microflora, which leads to a decrease in the contraceptive effectiveness of the drug;
- hypoglycemic agents, indirect anticoagulants - consideration should be given to adjusting their dosage regimen.
Analogs
Analogs of Triziston are: Tri-Mercy, Anteovin, Trikvilar, Gravistat 125, Tri-Regol, Mikroginon, Miniziston, Miranova, Rigevidon, Oralkon, Ovidon, Trinordiol.
Terms and conditions of storage
Keep out of the reach of children.
Store at temperatures up to 25 ° C.
The shelf life is 5 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Triziston
Few reviews of Trizistone confirm the high contraceptive efficacy of the drug. Women report good health on the background of long-term use of oral contraceptives and the absence of a significant increase in body weight.
In some cases, taking pills can cause mild nausea.
Price for Triziston in pharmacies
The price for Triziston for 1 package can range from 485 rubles.
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
